Peter Radovich Sells 3,143 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,143 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $302,325.17. Following the transaction, the chief operating officer directly owned 23,286 shares in the company, valued at approximately $2,239,880.34. This trade represents a 11.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $222,312.06.

Mirum Pharmaceuticals Price Performance

Shares of MIRM opened at $100.85 on Thursday. The business’s fifty day moving average is $78.97 and its 200 day moving average is $71.75. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $101.50. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The stock has a market cap of $5.18 billion, a P/E ratio of -117.27 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The firm had revenue of $133.01 million for the quarter, compared to the consensus estimate of $130.11 million. During the same quarter in the prior year, the company posted ($0.30) earnings per share. The business’s revenue was up 47.1% on a year-over-year basis. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Mirum Pharmaceuticals by 22.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,815 shares of the company’s stock worth $1,170,000 after buying an additional 2,700 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in Mirum Pharmaceuticals by 377.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,274 shares of the company’s stock worth $733,000 after buying an additional 7,332 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $240,000. Wetzel Investment Advisors Inc. purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $205,000. Finally, Palumbo Wealth Management LLC boosted its stake in Mirum Pharmaceuticals by 19.8% in the fourth quarter. Palumbo Wealth Management LLC now owns 5,082 shares of the company’s stock valued at $401,000 after acquiring an additional 840 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have commented on MIRM. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, December 11th. Citizens Jmp upped their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a report on Friday, December 19th. TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Leerink Partners set a $100.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, December 10th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $104.92.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.